A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer (Max Planck Research Unit for Enzymology of Protein Folding, Halle/Saale, Germany) and Dr. Frank Striggow (German Center for Neurodegenerative Diseases (DZNE)) have combined two already approved pharmaceutical substances with each other using a chemical linker structure...
Realtime Related Tweets
the monkees strikeforce davy jones love actually miesha tate vs ronda rousey idiocracy deep impact
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.